---
figid: PMC2844426__pone.0009872.g004
figtitle: Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral
  Sclerosis (ALS)
organisms:
- Bos taurus
- Oryctolagus cuniculus
- Capra hircus
- Homo sapiens
- Saccharomyces cerevisiae
- Gallus gallus
- Danio rerio
- Chlorocebus aethiops
- Derris trifoliata
- Mus musculus
- Bovine adenovirus 3
organisms_ner:
- Mus musculus
- Homo sapiens
- Gallus gallus
- Bos taurus
- Capra hircus
- Oryctolagus cuniculus
- Danio rerio
- Drosophila melanogaster
pmcid: PMC2844426
filename: pone.0009872.g004.jpg
figlink: /pmc/articles/PMC2844426/figure/pone-0009872-g004/
number: F4
caption: 'There are two main pathways through which MAP kinases signal: the classical
  MAPK pathway and the p38 MAP kinase pathway. In the classical signalling pathway,
  ligand binding results in receptor activation, which in turns leads to the activation
  of GRB2 and SOS. SOS catalyses the substitution of GDP for GTP on RAS (⇓), which
  then activates RAF1 (⇓). RAF1 subsequently phosphorylates MEK1/2, which in turn
  activate ERK1 and ERK2 (⇓). The ERK proteins activate MKNK2 (⇓), which is directly
  responsible for activation of proteins required for translation initiation. Downregulation
  of multiple core signalling components in combination with upregulation of the inhibitors,
  NF1 and PTPN5 predicts inability of the cell''s basal response to growth factors.
  The p38 MAPK pathway is a signalling cascade that is distinct, but not exclusive
  from the classical MAPK signalling pathway. As with the classical MAPK pathway,
  multiple elements of the pathway are downregulated: TAK1(⇓), p38 (⇓), MK2 (⇓) and
  HSP27 (⇓) which may result in a decrease in mRNA stability and the cell''s anti-apoptotic
  response. (PM = plasma membrane)'
papertitle: Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral
  Sclerosis (ALS).
reftext: Laura E. Cox, et al. PLoS One. 2010;5(3):e9872.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9511308
figid_alias: PMC2844426__F4
figtype: Figure
redirect_from: /figures/PMC2844426__F4
ndex: 070c3d9d-de94-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2844426__pone.0009872.g004.html
  '@type': Dataset
  description: 'There are two main pathways through which MAP kinases signal: the
    classical MAPK pathway and the p38 MAP kinase pathway. In the classical signalling
    pathway, ligand binding results in receptor activation, which in turns leads to
    the activation of GRB2 and SOS. SOS catalyses the substitution of GDP for GTP
    on RAS (⇓), which then activates RAF1 (⇓). RAF1 subsequently phosphorylates MEK1/2,
    which in turn activate ERK1 and ERK2 (⇓). The ERK proteins activate MKNK2 (⇓),
    which is directly responsible for activation of proteins required for translation
    initiation. Downregulation of multiple core signalling components in combination
    with upregulation of the inhibitors, NF1 and PTPN5 predicts inability of the cell''s
    basal response to growth factors. The p38 MAPK pathway is a signalling cascade
    that is distinct, but not exclusive from the classical MAPK signalling pathway.
    As with the classical MAPK pathway, multiple elements of the pathway are downregulated:
    TAK1(⇓), p38 (⇓), MK2 (⇓) and HSP27 (⇓) which may result in a decrease in mRNA
    stability and the cell''s anti-apoptotic response. (PM = plasma membrane)'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mapk14
  - Crk
  - Grap2
  - Syp
  - Ahsa1
  - Grb2
  - Nr2c2
  - Map3k7
  - Map2k6
  - Map2k3
  - ras
  - Hras
  - Kras
  - Rem1
  - Nf1
  - Raf1
  - Ear1
  - Map2k2
  - Map2k1
  - Kcna2
  - Mapkapk2
  - Ptpn5
  - Mapk1
  - Mapk3
  - Hspb2
  - Mknk2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - GRB2
  - MAP3K7
  - NR2C2
  - XYLT2
  - SOS1
  - SOS2
  - MAP2K6
  - MAP2K3
  - KRAS
  - HRAS
  - NRAS
  - NF1
  - RAF1
  - RNASE3
  - MAP2K2
  - MAP2K1
  - KCNA2
  - MAPKAPK2
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - PTPN5
  - HSPB1
  - HSPB2
  - MKNK2
  - TAB1
  - mapk14a
  - grb2b
  - rab1ab
  - nf1a
  - raf1a
  - map2k2a
  - map2k1
  - ptpn5
  - mapk3
  - hspb1
  - mknk2b
  - MKP-4
  - p38b
  - rl
  - p38a
  - p38c
  - lic
  - Nurf-38
  - Ebp
  - Hrb87F
  - drk
  - Tak1
  - Sos
  - Ras64B
  - Ras85D
  - Raf
  - MAPk-Ak2
  - Act5C
  - Act42A
  - Act57B
  - Act79B
  - Act88F
  - Act87E
  - Hsp27
  - Cardiomyopathy
  - Noonan syndrome
---
